Search Within

Aaron David Goldberg

Formats
  1. Meeting Abstract (61)
  2. Journal Article (30)
  3. Research Letter (6)
  4. Correspondence (3)
  5. Editorial (3)
  6. Review (2)
  7. Book Section (1)
Groups
  1. Adult Leukemia (106)
  2. Center for Hematologic Malignancies (106)
  3. Department of Medicine (106)
  4. Hematologic Malignancies, Division of (106)
  5. Weinberg Fellows (106)
  6. Hematology-Oncology Fellows (48)

More Groups

People
  1. Martin Tallman (46)
  2. Eytan Stein (38)
  3. Christopher Famulare (36)
  4. Ross Levine (20)
  5. Jan Bewersdorf (19)
  6. Andriy Derkach (18)

More People

Years
  1. 2025 (2)
  2. 2024 (11)
  3. 2023 (20)
  4. 2022 (15)
  5. 2021 (15)
  6. 2020 (15)

More Years

Publications
  1. Blood (55)
  2. Leukemia and Lymphoma (8)
  3. American Journal of Hematology (6)
  4. Blood Advances (5)
  5. Journal of Clinical Oncology (5)
  6. Haematologica (4)

More Publications

Publishers
  1. American Society of Hematology (60)
  2. Taylor & Francis Group (8)
  3. American Society of Clinical Oncology (6)
  4. John Wiley & Sons, Inc. (5)
  5. Ferrata Storti Foundation (4)
  6. Nature Publishing Group (4)

More Publishers

Results (106)

Export to EndNote / Excel | PubMed

Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Outcomes of patients with hematologic malignancies and COVID-19: A report from the ASH Research Collaborative Data Hub
    Journal Article

    Wood, W. A.; Neuberg, D. S.; Colton Thompson, J.; Tallman, M. S.; Sekeres, M. A.; Sehn, L. H.; Anderson, K. C.; Goldberg, A. D.; Pennell, N. A.; Niemeyer, C. M.; more...
    Blood Advances (2020)

    Fulltext@MSK | Save
  • Single-cell mutation analysis of clonal evolution in myeloid malignancies
    Journal Article

    Miles, L. A.; Bowman, R. L.; Merlinsky, T. R.; Csete, I. S.; Ooi, A. T.; Durruthy-Durruthy, R.; Bowman, M.; Famulare, C.; Patel, M. A.; Mendez, P.; more...
    Nature (2020)

    Fulltext@MSK | Save
  • Leukemia cell of origin influences apoptotic priming and sensitivity to LSD1 inhibition
    Journal Article

    Cai, S. F.; Chu, S. H.; Goldberg, A. D.; Parvin, S.; Koche, R. P.; Glass, J. L.; Stein, E. M.; Tallman, M. S.; Sen, F.; Famulare, C. A.; more...
    Cancer Discovery (2020)

    Fulltext@MSK | Save
  • Special considerations in the management of adult patients with acute leukaemias and myeloid neoplasms in the COVID-19 era: Recommendations from a panel of international experts
    Editorial

    Zeidan, A. M.; Boddu, P. C.; Patnaik, M. M.; Bewersdorf, J. P.; Stahl, M.; Rampal, R. K.; Shallis, R. M.; Steensma, D. P.; Savona, M. R.; Sekeres, M. A.; more...
    The Lancet Haematology (2020)

    Fulltext@MSK | Save
  • Venetoclax and hypomethylating agents (HMAs) induce high response rates in MDS, including patients after HMA therapy failure
    Journal Article

    Ball, B. J.; Famulare, C. A.; Stein, E. M.; Tallman, M. S.; Derkach, A.; Roshal, M.; Gill, S. I.; Manning, B. M.; Koprivnikar, J.; McCloskey, J.; more...
    Blood Advances (2020)

    Fulltext@MSK | Save
  • Camidanlumab tesirine, an antibody-drug conjugate, in relapsed/refractory CD25-positive acute myeloid leukemia or acute lymphoblastic leukemia: A phase I study
    Journal Article

    Goldberg, A. D.; Atallah, E.; Rizzieri, D.; Walter, R. B.; Chung, K. Y.; Spira, A.; Stock, W.; Tallman, M. S.; Cruz, H. G.; Boni, J.; more...
    Leukemia Research (2020)

    Fulltext@MSK | Save
  • Comparison of induction strategies and responses for acute myeloid leukemia patients after resistance to hypomethylating agents for antecedent myeloid malignancy
    Journal Article

    Talati, C.; Goldberg, A. D.; Przespolewski, A.; Chan, O.; Ali, N. A.; Kim, J.; Famulare, C.; Sallman, D.; Padron, E.; Kuykendall, A.; more...
    Leukemia Research (2020)

    Fulltext@MSK | Save
  • Leukemia stem cell gene expression signatures contribute to acute myeloid leukemia risk stratification
    Editorial

    Knorr, K. L. B.; Goldberg, A. D.
    Haematologica (2020)

    Fulltext@MSK | Save
  • Tolerability and efficacy of crenolanib and cytarabine/anthracycline chemotherapy in older patients (aged 61 to 75) with newly diagnosed FLT3-mutated acute myeloid leukemia (AML)
    Meeting Abstract

    Wang, E. S.; Griffiths, E. A.; Walter, R. B.; Tallman, M. S.; Goldberg, A. D.; Messahel, B.; Stone, R. M.
    Blood (2019)

    Fulltext@MSK | Save
  • Younger patients with newly diagnosed FLT3-mutant AML treated with crenolanib plus chemotherapy achieve adequate free crenolanib levels and durable remissions
    Meeting Abstract

    Goldberg, A. D.; Coombs, C. C.; Wang, E. S.; Walter, R. B.; Karanes, C.; Vigil, C. E.; Messahel, B.; Stone, R. M.; Collins, R. H.
    Blood (2019)

    Fulltext@MSK | Save